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Carvedilol: Therapeutic Application and Practice 
Guidelines 
Barry E. Bleske, Pharm.D., Edward M. Gilbert, M.D., FACC, and Mark A. Munger, Pharm.D., FCCP 
Current knowledge of the mechanisms contributing to progression of heart 
failure suggests that therapies that limit or interfere with the consequences of 
neurohormonal activation and improve myocardial energetics appear to be 
most beneficial. Carvedilol, a nonselective P-adrenergic blocker with 
peripheral vasodilating properties, reduces mortality, slows progression of 
disease, and improves quality of life in patients with heart failure when added 
to standard therapy. When administered according to recommended 
guidelines, carvedilol is well tolerated. Clinical guidelines on the use of 
carvedilol in heart failure are provided. 
(Pharmacotherapy 1998; 18(4): 729-737) 
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Conclusion 
“It should be the function of medicine to have 
Ernest L. Wynder 
Heart failure increases myocardial energy 
expenditure, thereby promoting pathologic 
remodeling, which accelerates cell death in the 
human failing heart  by overactivity of 
neurohormonal systems.’ Given this 
understanding of the pathophysiology of heart 
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people die young as late as possible.” 
failure, treatments that limit or interfere with 
neurohormonal activation or  improve the 
balance between myocardial oxygen supply and 
demand appear to be most promising.2 Results 
of 2 decades of basic and clinical research suggest 
that P-adrenergic blockers can prevent disease 
progression and are tolerated in selected patients. 
Carvedilol is the first P-adrenergic blocker 
approved for the treatment of heart failure. It 
improves ejection fraction, cardiac hemodynamics, 
New York Heart Association (NYHA) functional 
class, and ~ e l l - b e i n g . ~ ~  It slows the progression 
of the disease when added to conventional 
therapy, as evidenced by risk reductions for 
hospitalization and mortality6 Therapy must be 
managed carefully, however, to ensure these 
outcomes. 
Like other P-adrenergic blockers, carvedilol 
reduces adrenergic drive from the failing human 
heart, resulting in early clinical deterioration in 
many patients. With proper understanding of 
the common symptoms associated with initiation 
and up-titration of therapy, this short-lived 
deterioration can be managed safely Thereafter, 
patients experience long-term benefits from the 
agent. 
Rationale for P-Adrenergic Blockade in Heart 
Failure 
Heart failure prognosis has remained dismal 
over the past 4 decades despite reductions in 
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morbidity and mortality for most cardiovascular 
diseases. Results of large placebo-controlled 
clinical trials show that annual mortality ranges 
from approximately 15% in mild to moderate 
disease to 54% in  severe disease.", l1 An 
angiotensin-converting enzyme (ACE) inhibitor 
is considered the mainstay of therapy, but these 
agents result in only an approximate 10% annual 
reduction in  mortality.1°-12 Therefore, the 
challenge is to develop new treatment strategies 
that will decrease the high risk of dying from this 
syndrome. 
The rationale for prescribing P-adrenergic 
blocking agents is founded on knowledge that 
heart failure is a chronically activated adrenergic 
state. Over the past 2 decades, studies described 
an association between progression of left ven- 
tricular dysfunction and greater norepinephrine 
~pillover.'~ As a result of increased myocardial 
interstitial norepinephrine concentration, poor 
left ventricular dysfunction is associated with 
several changes in the P-adrenergic receptor 
complex. These include PI-receptor down- 
regulation, uncoupling of the Pl-receptor, 
increases in al-receptor density, and decreased 
density of the AT1-receptor (angiotensin II).13- l4 
In patients with heart failure, the outcome of 
these P-adrenergic system changes is a reduction 
in  myocyte contractility with an  associated 
diminished ability to respond to dynamic stress,15 
resulting in  chronic fatigue. In  addition, 
norepinephrine is directly toxic, thereby 
accelerating cardiac myocyte death.I6 The end 
result of these changes is progression of disease 
and poor survival. 
In  theory, P-adrenergic blockade could 
attenuate changes in the cardiac sympathetic 
nervous system and slow disease progression. 
Potential benefits include reduced autonomic 
tone, resulting in a decrease in resting energy 
demands of the failing human heart, improved 
cardiac metabolic and hemodynamic status, 
attenuation of myocyte necrosis, and prevention 
of sympathetic-mediated arrhythmogenesis. In 
long-term clinical trials, carvedilol was associated 
with improvements in heart failure when added 
to ACE inhibitors with or without diuretics and 
d i g o ~ i n . ~ ~  
Pharmacology 
Carvedilol is a racemic arylethanolamine with 
nonselective P-adrenergic-blocking and  
peripheral vasodilating properties. The P- 
adrenergic-blocking activity occurs without 
intrinsic sympathomimetic activity and only with 
the levorotatory configuration. l 7  Moderate 
arteriolar dilation and reductions in peripheral 
vascular resistance occur through al-adrenergic 
receptor blockade.18-20 The al-antagonist  
properties occur at equal potency from both 
dextrorotatory and levorotatory enantiomers.2' 
At  therapeutic dosages, carvedilol inhibits P1 > 
a1 > Pz-receptors at a ratio ofil:3:7, respectively.22 
Blockade of P-receptors should result in  
normal P-adrenergic receptor biology. Carvedilol, 
however does not up-regulate 6-adrenergic 
receptors. This may be due to guanine nucleotide 
binding, a process whereby high concentrations 
of guanine nucleotides (similar in structure to 
carvedilol) competitively antagonize P-adrenergic- 
blocker receptor binding.20- 23 Despite competitive 
pharmacologic binding, adenylate cyclase actkity 
is not elevated with carvedilol, suggesting signal 
transduction is Lot restored and therefore the 
heart is protected from adrenergic stimulation.22 
Further protection against 'chronic adrenergic 
activation is evidenced by a decrease in  
transmyocardial norepinephrine production with 
long-term dosing. 24 
P-Adrenergic blockers also reduce adrenergic 
drive to the heart through inverse agonism.22s 25* 26 
Unoccupied or  nonstimulated adrenergic 
receptors retain intrinsic activity that can support 
myocardial contractility. Inverse agonism is a 
process whereby P-adrenergic blockers inactivate 
these unoccupied 277 28 Ca rvedilol has 
the least amount of this property among commer- 
cially available P-adrenergic blockers. Independent 
of the degree of inverse agonism, this property 
contributes to myocardial depression on starting 
carvedilol therapy 
Ancillary Properties 
Carvedilol has a number of cardioprotective 
properties that may be beneficial in heart failure. 
It reduces hypoxic stress-induced glycogen loss 
from myocardial tissue compared with equivalent 
doses of propranolol in ~ i t r o . ~ ~  Although the 
exact mechanism of these effects is unknown, 
carvedilol inhibits oxygen free radical lipid 
oxidation in rat brain and heart tissue and in 
human in vitro studies, and inhibits superoxide 
release from phorbol ester-activated n e u t r o p h i l ~ . ~ ~ ~ ~  
These antioxidant properties occur in clinically 
observed plasma  concentration^.^^ 
Results of animal studies indicate that the drug 
inhibits vascular smooth muscle cell proliferation 
and migration.34 This suggests that it has cardio- 
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protective effects in patients with underlying 
atherosclerosis. The clinical significance of these 
findings is unknown. 
Pharmacokinetics 
The agent undergoes rapid and extensive 
absorption with a large first-pass metabolic effect 
resulting in only 25% absolute bi~availability.~~ A 
2-fold bioavailability difference exists between 
the dextrorotatory (31%) and the levorotatory 
configurations (15%) .36 The compound is highly 
lipophilic, thereby exhibiting a large volume of 
d i ~ t r i b u t i o n . ~ ~  Carvedilol is highly protein 
bound to albumin.38 It is extensively metabolized 
by cytochrome P450 (CYP) 2D6 and CYPZC9 
microsomes, which show genetic polymorphism. 
The result is three active metabolites, of which 
the 4'-hydroxyphenyl metabolite has 13-fold 
greater P-adrenergic-blocking activity than the 
parent compound.39 The predominant excretion 
pathway is through bile. 
Clinical Outcomes 
Most clinical trials of carvedilol employed 
consistent research methods. The agent was 
added to a background therapy of ACE inhibitors 
plus diuretics and/or digoxin. Calcium channel 
blockers, other P-adrenergic blockers, and 
vasodilators, with the exception of long-acting 
nitrates and hydralazine, were excluded. Patients 
were first enrolled in an open-label run-in phase 
lasting from 24 hours-3 weeks to evaluate 
tolerance. If they tolerated the P-adrenergic 
blocker, they moved to a dose-escalation phase of 
4-6 weeks. Exposure to carvedilol was generally 
3-6 months. Most patients were in  NYHA 
functional class 11-111 heart failure with relatively 
even distribution between idiopathic dilated and 
postinfarction cardiomyopathy. 
Cardiac Hemodynamics and Left Ventricular 
Effects 
Carvedilol therapy in  patients with heart 
failure results in significant improvement in left 
ventricular hemodynamics, which occurs at a 
substantially lower double product (systolic 
blood pressure x heart rate) than baseline values. 
Significant increases occur in cardiac output and 
are associated with improvements in  stroke 
volume and stroke work indexe~ .~ .  The drug 
causes in modest falls in  systemic vascular 
resistance and mean arterial pre~sure.~.  43  Heart 
rate decreases in a dose-related manner, with a mean 
decrease of approximately 12-13 beats/minute at 
a mean dosage of 45 mg/day4' 
Long-term administration of the agent results 
in significant improvement in left ventricular 
ejection fraction. Improvement occurs only with 
long-term dosing, is dose dependent, with greater 
increases occurring with dose escalation, and is 
independent of heart failure eti~logy.~ The exact 
mechanisms related to the improvement in  
ejection fraction are unknown. 
Exercise Tolerance 
Results of clinical exercise tolerance studies 
with carvedilol reported minimal improvement in 
exercise capacity. In tests of maximum energy 
expenditure the drug led to no change in exercise 
tolerance, perhaps due to blunting of maximum 
heart rate.3- Submaximum tests yield mixed 
results, confirming the limitation of these tests is 
due to patient e f f ~ r t . ~ - ~ #  9. 24 Although peak 
exercise remains stable with carvedilol therapy, 
exercise performance is maintained a t  a 
significantly lower double product, suggesting 
improved cardiac efficiency. 
Symptom and Global Assessment Outcomes 
Carvedilol was extensively evaluated by 
symptom measures and global assessment 
outcomes. It significantly improves NYHA 
functional class.3* 4 9  6-9 It also improves symptom 
scores3- 4- ' and patient and physician global 
assessments of the heart failure ~ t a t e . ~ - ~  Quality 
of life measured by the Minnesota Living with 
Heart Failure questionnaire showed no change.*. 
This may reflect length of therapy, problems with 
measuring quality of life with this instrument, 
differences in  clinical experience among 
investigators, or unfavorable effect on quality of 
life of P-adrenergic blockers. Since other studies 
showed P-adrenergic blockers improved quality 
of life after 12-18 months, length of follow-up is 
the most probable explanation. 
Morbidity and Mortality 
Clinical progression of heart failure may be 
defined by death, hospitalization, increased drug 
requirements, and decline in left ventricular 
function or exercise tolerance. A stratified 
analysis of four studies randomizing 1094 
patients with NYHA functional class 11-IV heart 
failure followed for a mean of 6.5 months showed 
a significant 65% reduction in mortality, 7.8% in 
the placebo group and 3.2% in the carvedilol 
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group.ws41 The mortality risk reduction was due 
to decreases in both progressive heart failure and 
sudden death. The risk of hospitalization for the 
disease was reduced 36% and length of stay per 
patient decreased by 1.4 days. Reductions were 
also noted in the need for sustained increases in 
heart failure drugs. Benefits were seen in all 
subgroups stratified by age, sex, race, severity 
and etiology of disease, and concomitant therapy 
Clinical Guidelines 
Carvedilol is indicated for the treatment of 
mild to moderate (NYHA functional class 11-111) 
disease due to left ventricular systolic dysfunction. 
I t  had clinical benefit i n  patients receiving 
standard therapy with an ACE inhibitor with or 
without diuretics and digitalis, and it should 
therefore be prescribed in combination with 
these drugs. Carvedilol, however, should not be 
considered as a fourth-line agent, since reduction 
of disease progression is not firmly established 
with all the standard drugs.42 Once the decision 
is made to start carvedilol therapy, clinical 
guidelines must be understood and followed to 
ensure the best clinical outcomes (Figure 1). 
This drug should be prescribed only for  
patients whose heart failure is clinically stable, 
defined by stable dosing of standard agents ke. ,  
no dosage changes in ACE inhibitors for 1 mo 
and diuretics for 2 wks) and without the need for 
intravenous inotropic support for at least 30 
days, those with optimal filling pressures, and 
those with an absence of contraindications to P- 
adrenergic blockers. Experience with carvedilol 
is limited in  patients with severe, NYHA 
functional class IV disease; these patients are the 
subject of an ongoing trial (COPERNICUS). The 
agent can be prescribed for these patients, but 
only by cardiologists experienced in  the 
management of P-adrenergic blockers in heart 
failure. Patients considered for carvedilol 
therapy should have no evidence of low volume 
status (dry mucous membranes, orthostatic blood 
pressure changes, decreased urinary output) or 
signs and symptoms of excessive fluid volume 
(weight gain, radiographic evidence of pulmonary 
edema, increased jugular venous pressure, 
enlarged or tender liver, peripheral edema). 
Several contraindications to carvedilol therapy 
exist. Briefly, decompensated heart failure, 
patients with clinical evidence of bronchitis or 
asthma maintained with bronchodilators or 
steroids and/or forced vital capacity (FVC)/forced 
expiratory volume in  1 second (FEV1) below 
60%, symptomatic peripheral vascular disease, 
brittle insulin-dependent diabetes (repeated 
episodes of ketoacidosis, hyperglycemic coma, 
hypoglycemic shock), severe bradycardia, sick 
sinus syndrome, second- or third-degree heart 
block unless paced, standing systolic blood 
pressure below 85 mm Hg, and hepatic injury 
defined by a rise in transaminase level 3 times 
upper limit of normal should generally not 
receive the agent. 
The patient’s drug profile should be examined 
for possible interactions (Table 1). Carvedilol is 
metabolized by CYP2D6 and CYP2C9 microsomes. 
Inhibition of the clearance of its metabolism 
through the CYP2D6 isozyme would be expected 
to increase the dextrorotatory enantiomer 
concentration, producing greater al-adrenergic 
blockade and leading to an increased likelihood 
of episodic hypotension. Inhibitors of CYP2C9 
increase the levdrotatory enantiomer concentration, 
producing greater (3-adrenergic blockade, and 
result i n  the possibility of more profound 
bradycardia or overt heart failure. Carvedilol 
increases serum digoxin concentrations by 15%.43 
This interaction may lead to greater atrioventricular 
nodal conduction blockade, resulting in lower 
heart rates. Strong inducers of CYPZC9 such as 
rifampin decrease carvedilol serum concentrations 
by approximately 70%. 
These interactions should be anticipated before 
carvedilol is administered and if necessary, 
contributing agents should be discontinued or 
their dosages decreased. When the interacting 
drug may not be discontinued or its dosage 
decreased, it should be understood that reaching 
the target dosage of carvedilol may not  be 
possible or perhaps reasonable. 
Pharmacodynamic interactions also should be 
evaluated. Conduction disturbances may occur if 
carvedilol is coadministered with drugs with 
sinoatrial or atrioventricular nodal-blocking 
properties such as verapamil, diltiazem, and 
mibefradil. Drugs that have negative inotropic 
properties such as verapamil and diltiazem 
should generally be avoided in patients with 
heart failure, and especially in  those who are 
candidates for carvedilol. Symptomatic hypo- 
tension is more likely to occur if carvedilol is 
coadministered with other vasodilating agents 
(ACE inhibitors, calcium channel blockers, 
hydralazine), especially at the same time of day. 
Although this is patient and drug specific, 
separating drug administration times may be 
prudent at the start of carvedilol therapy in 
patients receiving one or, especially, two or more 
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.1 or Discontinue 
diuretics 
.1 or 
Discontinue 
Carvedilol 
733 
CaNedilOl Practice Guideline 
Indicators 
NYHA FC 11-111 
ACE Inhibitors 
Diuretics 
Determine 
presence of 
drug interactions 
Table 1 
present 
offending 
medication 
if reasonable 
Symptomatic 
Bradycardia 
level andor d/c 
Carvedilol 
Consider 
Permanent 
Pacemaker 
Worsening 
Failure 
T Diuretics 
Carvedilol 
If Indicated 
8 lnotropes 
Nitroprusside 
\I/ 
Initiate Carvedilol 
3.125 mg BID 
Monitor BPRlR x 1 hour 
Unstable 
appropriate Discharge 
treatment, home 
d c  carvedilol, 
then discharge 
home 
\L 
Consider .1 
Ace Inhibitor1 
vasodilator or 
diuretic doses 
\L 
Rechallenge I A  L / \  
Discontinue I /  \ 
Appropriate 
Continue follow-up 
Carvedilol 
I 
If appropriate reconsider 
reinstitution, or uptritration 
of ACE inhibitor, or other J drug therapies 
Figure 1. Guidelines for starting and titrating carvedilol therapy. *The order of intervention should be based on clinical 
presentation. 
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Table 1. Suspected or Known Drug Interactions with Carvedilol Therapy in Heart Failure 
Drug Interaction Potential Outcome 
CYPZD6 inhibition 
CYPZD6 inhibition 
1' R(+) enantiomer, hypotension 
'? R(+) enantiomer, hypotension 
Quinidine" 
Fluoxetine, 
Paroxetine" 
Sertraline" 
Cime tidineb 
MibefradiP 
Amiodarone" 
Fluoxetine" 
Cime tidineb 
Omeprazole" 
Rifampinb 
Digoxinb 
Verapamil, 
Diltiazemb 
Clonidineb 
cat echolamine-depleting 
Mibefradil, 
Insulin" 
agents (reserpine) 
CYPZD6 inhibition 
CYPZD6 inhibition 
CYPZD6 inhibition 
CYPZD6 inhibition 
CYPZD6 inhibition 
CYPZC9 inhibition 
CYPZC9 inhibition 
CYPZC9 inhibition 
CYPZC9 induction 
Unknown 
Pharmacodynamic 
Pharmacodynamic 
Pharmacodynamic 
Pharmacodynarnic 
Pharmacodynamic 
Pharmacodynamic 
_ -  
'T' R(+) enantiomer, hypotension 
1' R(+) enantiomer, hypotension 
t R(+) enantiomer?' hypotension 
? R(+) enantiomer, hypotension 
? R(+) enantiomer, hypotension 
1' S(-) enantiomer, 1 HR, hypotension 
1' S(-) enantiomer," 1 HR, hypotension 
t S(-) enantiomer, 1 HR, hypotension 
1 s(-) enantiomer, t HR 
? digoxin serum conc 15%43 
? AV nodal blockade, 1 HR, hypotension 
? AV nodal blockade, 1 HR, hypotension 
1 HR, hypotension 
1 HR, hypotension 
(1 carvedilol plasma conc 70%)39 
(? AV nodal blockade, 1 HR) 
? AV nodal blockade, 1 HR, hypotension 
Potentiate 1 blood sugar 
Oral hypoglycemics 
HR = heart rate; AV = atrioventricular; C, = maximum concentration. 
"Suspected drug interaction. 
bKnown drug interaction. 
I 
vasodilating drugs. A reasonable suggestion is to 
administer carvedilol and other vasodilators 
approximately 2 hours apart. 
An important step before starting carvedilol 
therapy is patient education. The drug does not 
typically result in short-term symptomatic benefit 
due to withdrawal of adrenergic drive to the 
heart. Rather, it reduces chronotropic and inotropic 
support, potentially leading to deterioration in 
many patients. Typically, long-term benefit 
occurs after 1-2 months, so patient education is 
absolutely necessary to avoid premature 
discontinuation. Patients should understand 
common symptoms that occur, and that in some 
cases reassurance is all that is necessary, whereas 
in others symptoms can be effectively managed 
by adjustments in dosages of other drugs. 
It is extremely important that patients know 
that i t  may be several weeks before they 
experience improvement in  heart failure. 
Education will diminish the number of patients 
who become noncompliant when beginning 
therapy or up-titrating the dose, and lead to 
fewer therapeutic failures. 
The initial dosage of carvedilol is 3.125 mg 
twicdday for 2 weeks. It may be doubled (6.25, 
12.5, and 25 mg) every 2 weeks to a maximum of 
50 mg twicdday in patients weighing more than 
85 kg, or 25 mg twice/day in those weighing 
under 85 kg. Clinical trials suggest that more 
than 90% of patients can be successfully titrated 
to target dosages.39 Patients may be managed in a 
clinic setting for evaluation of response, with 
orthostatic blood pressure and heart rate 
measured at peak concentrations (30 min-1 hr) 
before the dosage is changed. The dosage may be 
titrated upward based on standing systolic blood 
pressure and heart rate responses. 
At  the start of therapy or during titration, 
patients should be observed for signs of dizziness 
or lightheadedness for at least 1 hour after 
dosing. With each dosing change patients should 
be cautioned about driving or other hazardous 
activities. These recommendations are in the 
package insert and therefore should be followed, 
without exception, to avoid legal problems. If 
systolic blood pressure is above 85 mm Hg, heart 
rate is greater than 55 beatdminute, and the 
patient is asymptomatic, titration may proceed 
and continue until target dosages or intolerable 
adverse effects occur. To avoid intolerance 
associated with peak drug concentrations, 
carvedilol should be taken with food, which 
slows absorption but does not affect the extent of 
bioavailabili ty. 
Similar to other P-adrenergic blockers, 
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carvedilol should not be discontinued abruptly 
and should be tapered off. Before surgery, the 
dosage may be halved, but therapy should be 
continued to avoid reverting to dosages at the 
start of therapy and up-titration schedules. 
In clinical trials the discontinuation rate of 
carvedilol was approximately 5%.40 The primary 
reasons were bradycardia, episodic hypo tension 
(dizziness), and worsening heart failure. If the 
heart rate drops below 55 beatdminute, the 
dosage should be adjusted (decreased one-half) 
or discontinued, and the patient should undergo 
further medical evaluation. If the patient is 
taking other arteriovenous nodal conduction 
drugs, consideration should be given to discon- 
tinuing those agents. Digoxin serum concen- 
trations should be assessed. An alternative to dis- 
continuation is permanent pacemaker placement, 
which is well tolerated with carvedilol. 
Excessive hypotension or syncope can be 
treated by discontinuing diuretics or reducing 
dosages of ACE inhibitors or other vasodilators 
by half. If hypotension or syncope requires ACE 
inhibitor dosage reduction or discontinuation, it 
is important to reinstitute the ACE inhibitor after 
the patient has been stabilized with carvedilol. 
Worsening heart failure typically is associated 
with excessive fluid retention (peripheral edema, 
weight gain, shortness of breath). Fluid retention 
often responds to increased dosages of the 
diuretic or ACE inhibitor. These changes can 
often be handled in an outpatient setting. If  
symptoms persist, the carvedilol dosage may also 
have to be decreased or, occasionally, the drug 
discontinued. If cardiogenic shock occurs, the 
patient may be hospitalized and intermittent low- 
dose inotropic (dobutamine) or vasodilator 
(nitroprusside, nitroglycerin) therapy with 
concomitant carvedilol may be prescribed, or 
carvedilol may be d i s ~ o n t i n u e d . ~ ~  Carvedilol 
should not be reinstituted or the dosage titrated 
up until bradycardia, hypotension, or worsening 
heart failure is stabilized. 
Guidelines for reinstituting the drug are listed 
in Table 2.* In patients who develop worsening 
heart failure when beginning carvedilol, reinsti- 
tution of the agent results in clinical improve- 
ment similar to that in patients who tolerated the 
initial dosage.45 Therefore, the chances for 
clinical success appear to be equivalent for 
patients who are tolerant and intolerant to the 
first dose. Renal insufficiency occasionally 
develops in patients with preexisting vascular 
disease, renal disease, and low blood pressure 
(systolic blood pressure c 100 mm Hg). Dosage 
Table 2. Guidelines for Reinstituting of Carvedilol after 
Disc~ntinuation~~ 
Time off Carvedilol Guideline 
< 72 hrs 
> 72 hrs to < 7 days 
2 7 days 
Restart at same dosage before 
Restart at half dosage before 
Restart at 3.125 mg b.i.d. 
discontinuation. 
discontinuation. 
reduction or discontinuation of diuretics or other 
vasodilators and weekly monitoring of serum 
creatinine should be considered. 
A question clinicians may face is whether or 
not patients who are taking another P-adrenergic 
blocker should be changed to carvedilol. Clinical 
trials suggest an affirmative answer, although 
several courses of action may be considered. If 
patients have a positive clinical response to the 
current P-adrenergic blocker (increased left 
ventricular ejection fraction > 5 ejection units, no 
progression of disease defined by need for 
hospitalization or sustained increases in dosage), 
changing to carvedilol will most likely add little 
benefit.  If patients have not  shown these 
responses, tolerance to the current P-blocker 
should be assessed. If patients demonstrated 
intolerance at the start of therapy or during 
titration of the current P-adrenergic blocker, 
carvedilol 3.125 mg may be prescribed and 
dosing guidelines followed. For those who 
tolerate the current P-adrenergic blocker, 
carvedilol should be started at the next lowest 
dosage level; that is, if the dose of metoprolol is 
50 mg or greater, then start carvedilol dosage at 
6.25 mg twicdday due to combined P- and cy1- 
adrenergic blockade; titrate to target dosages. 
The change to carvedilol may be begun the day 
after discontinuing metoprolol. 
Conclusion 
Carvedilol is a n  important agent for the 
treatment of heart failure. Clinical trials showed 
that when added to standard heart failure 
therapy, i t  reduces the risk of mortality, slows 
progression of disease, and improves quality of 
life measures. Providing patient education, 
following prescribing guidelines, and performing 
appropriate monitoring will minimize intolerance 
while providing maximum benefit of this drug. 
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